Monitoring breast cancer progression through circulating methylated GCM2 and TMEM240 detection.

ABSTRACT:

Background

Breast cancer is the most commonly diagnosed cancer and the second leading cause of cancer-related deaths in women worldwide. Approximately 20-30% of women diagnosed with early-stage breast cancer eventually develop metastatic disease. Current biomarkers, such as CA15-3 and CEA, detect metastasis in only 60-80% of cases, underscoring the need for improved diagnostic tools. This study investigates the potential of circulating methylated GCM2 and TMEM240 as biomarkers for noninvasive monitoring of breast cancer progression.

Methods

In a prospective study conducted in Taiwan, 396 patients were enrolled, alongside a retrospective study of 134 plasma samples from Western populations. cfDNA was extracted, subjected to sodium bisulfite conversion, and the methylation lev

SUBMITTER: Hung CS 

PROVIDER: S-EPMC12281721 | biostudies-literature | 2025 Jul

REPOSITORIES: biostudies-literature